Regulatory Intelligence as the Basis for Regulatory Strategy and Global Drug Development
Regulatory Intelligence as the Basis for Regulatory Strategy and Global Drug Development

Author: Petra Heyen

Publisher: GRIN Verlag

Published: 2011

Total Pages: 89

ISBN-13: 3640862570

DOWNLOAD EBOOK

Master's Thesis from the year 2004 in the subject Health - Miscellaneous, grade: sehr gut, University of Bonn (Mathematisch-Naturwissenschaftliche Fakultät), language: English, abstract: The Regulatory Affairs (RA) department is a key discipline in the global network of drug development. During drug development, regulatory strategy is one crucial success factor for the approval of the development candidate. Also, regulatory strategy can optimise labelling in the key countries in order to maximise the market success. No submission and approval would be possible without the appropriate dossier composition and compilation. Without adherence to the respective guidance documents and scientific advice from Health Authorities to design the optimal clinical development plan, optimal labelling would not be feasible. These two examples show some characteristics of the regulatory strategy: it is highly interactive with other disciplines and it is heavily based on a thorough intelligence work which enables the RA Manager to know the "rules of the game" and to develop the optimal regulatory strategy for the current development candidate. The major cornerstone for developing a regulatory strategy is regulatory intelligence. This document focuses on regulatory intelligence. The regulatory contributions to the global drug development from early research to submission are described. Strategies for generic drugs as well as detailed strategies for life-cycle management are excluded. Major components of regulatory intelligence are: - Competitor Information - Information on Regulatory Environment - Information on Legal Requirements Competitor analysis is an essential aspect of the intelligence work. Sources of competitive information as well as relevant items of competitive information are described. Sources of information about the regulatory environment and sources of information about the legal regulatory environment are described and their tremendous impact on setting up and modify

Pharmaceutical Competitive Intelligence for the Regulatory Affairs Professional
Pharmaceutical Competitive Intelligence for the Regulatory Affairs Professional

Author: Raymond A. Huml

Publisher: Springer Science & Business Media

Published: 2012-06-15

Total Pages: 94

ISBN-13: 1461436826

DOWNLOAD EBOOK

This Brief defines competitive intelligence (CI) as a tool for making investment decisions within the pharmaceutical industry. It provides an overview of processes that the regulatory affairs professional must take into account when evaluating data impacting product-based risk evaluations. These apply particularly to evaluations that focus on outputs such as regulatory approval, or the commercial impact of product labeling on the sales forecast over a limited timeframe. The Brief also provides an overview of intellectual property assessment that can impact a product’s lifespan on the market due to patent protection itself (or loss of patent protection) or via regulatory exclusivity. Case examples are discussed to illustrate the importance of keeping up with the ever-changing regulations, and how to interpret them in the context of CI. In addition, there is a section on virtual data rooms (VDRs) which currently function as the cornerstone of due diligence investigations. While aimed primarily at regulatory affairs professionals in the United States, this publication provides a useful adjunct for other pharmaceutical executives, especially those new to product-based investments, and regulatory affairs professionals in other regions. ​

Medical Product Regulatory Affairs
Medical Product Regulatory Affairs

Author: John J. Tobin

Publisher: John Wiley & Sons

Published: 2023-08-29

Total Pages: 341

ISBN-13: 3527688986

DOWNLOAD EBOOK

Medical Product Regulatory Affairs Hands-on guide through the jungle of medical regulatory affairs for every professional involved in bringing new products to market Based on a module prepared by the authors for an MSc course offered by the University of Limerick, Ireland, Medical Product Regulatory Affairs is a comprehensive and practical guide on how pharmaceutical and medical devices are regulated within the major global markets. The Second Edition builds on the success of the first with an even wider scope and full coverage of new EU regulations on the safe use of medical devices. Following a look at drug development, complete sections are devoted to national and EU regulatory issues, manufacturing license application and retention, and regulation in the USA. Other topics dealt with include CDER, CBER and marketing and manufacturing licenses, the ICH process and Good Laboratory/Clinical/ Manufacturing Practices. Medical Product Regulatory Affairs includes information on: Aims and structure of regulation, covering purpose and principles of regulation, national and EU legislative processes, and pharmacopeia Regulatory strategy, covering product development and manufacturing, market vigilance, quality assurance systems, personnel, and documentation Drug discovery and development, covering prescription status, physical properties, therapeutic use, and drug discovery, development, and delivery Non-clinical studies, covering non-clinical study objectives and timing, pharmacological and pharmacodynamic studies, and bioavailability and bioequivalence Clinical trials, covering trial protocol, monitoring of trials, trial master files, and FDA communications The wide coverage of different product types and the main global markets makes Medical Product Regulatory Affairs ideal for training courses on regulatory affairs in academia and industry. It is also a valuable reference for pharmacologists, bioengineers, pharma engineers, and students in pharmacy to familiarize themselves with the topic.

International Regulatory Harmonization Amid Globalization of Drug Development
International Regulatory Harmonization Amid Globalization of Drug Development

Author: Institute of Medicine

Publisher: National Academies Press

Published: 2013-11-24

Total Pages: 129

ISBN-13: 0309284791

DOWNLOAD EBOOK

The past several decades have been a time of rapid globalization in the development, manufacture, marketing, and distribution of medical products and technologies. Increasingly, research on the safety and effectiveness of new drugs is being conducted in countries with little experience in regulation of medical product development. Demand has been increasing for globally harmonized, science-based standards for the development and evaluation of the safety, quality, and efficacy of medical products. Consistency of such standards could improve the efficiency and clarity of the drug development and evaluation process and, ultimately, promote and enhance product quality and the public health. To explore the need and prospects for greater international regulatory harmonization for drug development, the IOM Forum on Drug Discovery, Development, and Translation hosted a workshop on February 13-14, 2013. Discussions at the workshop helped identify principles, potential approaches, and strategies to advance the development or evolution of more harmonized regulatory standards. This document summarizes the workshop.

Strengthening a Workforce for Innovative Regulatory Science in Therapeutics Development
Strengthening a Workforce for Innovative Regulatory Science in Therapeutics Development

Author: Institute of Medicine

Publisher: National Academies Press

Published: 2012-04-04

Total Pages: 118

ISBN-13: 0309222176

DOWNLOAD EBOOK

The development and application of regulatory science - which FDA has defined as the science of developing new tools, standards, and approaches to assess the safety, efficacy, quality, and performance of FDA-regulated products - calls for a well-trained, scientifically engaged, and motivated workforce. FDA faces challenges in retaining regulatory scientists and providing them with opportunities for professional development. In the private sector, advancement of innovative regulatory science in drug development has not always been clearly defined, well coordinated, or connected to the needs of the agency. As a follow-up to a 2010 workshop, the IOM held a workshop on September 20-21, 2011, to provide a format for establishing a specific agenda to implement the vision and principles relating to a regulatory science workforce and disciplinary infrastructure as discussed in the 2010 workshop.

The Impact of Regulation On Drug Development
The Impact of Regulation On Drug Development

Author: G H Hennings

Publisher: Elsevier

Published: 2025-01-31

Total Pages: 0

ISBN-13: 190881859X

DOWNLOAD EBOOK

The impact of regulation on drug development provides the reader with a basic understanding of the evolution of global regulatory standards relevant to the research and development process of medicinal products and the role regulatory science plays, i.e. the science of developing new tools, standards and approaches to assess the safety, efficacy, quality and performance of regulated products. In light of the high-growth expectations of international investors, the increasing costs of research and development, and the challenges to patent protection, the pharmaceutical industry is in urgent need of substantial improvements in research and development productivity. The global framework of national legislations, (partly) harmonised guidelines and their evolution provides challenges and opportunities to an efficient management of the R&D process, which should be targeted to receive timely marketing authorisations and viable pricing and reimbursement decisions. Standard R&D strategies established originally for small molecules have to be intensively reviewed against this regulatory frame. This is particularly true if development projects are derived from biotechnological processes such as recombinant DNA technology, controlled expression of genes coding for biologically active proteins in prokaryotes and eukaryotes including transformed mammalian cells, hybridoma and monoclonal antibody methods or advanced therapy medicinal products such as gene or somatic cell therapy or tissue engineered products. Scientific (and regulatory) advice provided by health authorities should be considered as a potential value-increasing instrument in order to focus and streamline the R&D process. This book provides practical guidance on how to obtain such advice efficiently and how it is incorporated in global regulatory planning and strategies. Covers the impact of globally harmonised regulatory requirements on the different sectors of drug development regarding quality, safety and efficacy and their timing from discovery to the post-authorisation phase Examines the crucial role of scientific (and regulatory) advice and practical steps on how to obtain it effectively Establishes flexible global regulatory planning and strategies

Fundamentals of Drug Development
Fundamentals of Drug Development

Author: Jeffrey S. Barrett

Publisher: John Wiley & Sons

Published: 2022-09-07

Total Pages: 516

ISBN-13: 1119691699

DOWNLOAD EBOOK

Fundamentals of DRUG DEVELOPMENT Enables readers to understand the process of pharmaceutical research, its regulatory basis, and how it fits into the global healthcare environment This book discusses how to conduct pharmaceutical research and the context for how the industry fits into global healthcare. Holistically, the well-qualified author helps readers and students of drug development appreciate the time and expense of the process. Specifically, the work identifies the emerging trends shaping the future of drug development, along with important related topics like generic drugs, data sharing, and collaboration. To aid in seamless reader comprehension, the book includes a glossary of terms and a self-assessment quiz for each chapter at the end. PowerPoint slides are also available as an online ancillary for adopting professors. Sample topics covered in the book include: Drug development and its phases Decision-making processes, drug development milestones, and compound progression metrics The various disciplines involved along with an assessment of the complexity and risks associated across the stages of development Differences in the nature and scope of development programs due to the therapeutic area of interest Associated costs and resources required Graduate students and professors teaching courses in drug development, drug discovery, pharmaceuticals, medicinal chemistry, and drug synthesis will be able to use this book as a complete resource for understanding all the complexities and nuances involved in the drug development process.

International Cooperation, Convergence and Harmonization of Pharmaceutical Regulations
International Cooperation, Convergence and Harmonization of Pharmaceutical Regulations

Author: Pierre-Louis Lezotre

Publisher: Academic Press

Published: 2013-12-05

Total Pages: 377

ISBN-13: 0128005696

DOWNLOAD EBOOK

International Cooperation, Convergence and Harmonization of Pharmaceutical Regulations: A Global Perspective provides the current status of the complex and broad phenomenon of cooperation, convergence and harmonization in the pharmaceutical sector (Part I), thoroughly evaluates its added value and its critical parameters and influencing factors (Part II) in order to recommend actions and measures to support the next steps for cooperation, convergence and harmonization (Part III). All of these recommendations in the book support the establishment of a better coordinated global pharmaceutical system which represents the best realistic alternative to fulfill the objective to establish a global coalition of regulators and to respond to an increased demand to further cooperation in the pharmaceutical sector. This proposed framework, which leverages all of the ongoing positive cooperation initiatives and uses as foundations all of the numerous harmonization projects developed over the years, presents advantages for all stakeholders and would definitively have significant added value to the promotion and protection of global public health. The status of all major worldwide harmonization and cooperation initiatives (at bilateral, regional, and global levels) The value of cooperation in the pharmaceutical sector and the driving factors behind harmonization The proposition of a structure for the global pharmaceutical system and timely recommendations for enhancing international cooperation, as well as further discussion and policy changes in this area